Optimizing Management of Lupus Nephritis

Alvin Wells, MD, PhD, opens a discussion surrounding systemic lupus erythematosus (SLE) and lupus nephritis (LN).

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Jorge Larranaga, MD, and Alvin Wells, MD, PhD, describe the progression of SLE to lupus nephritis.

Jorge Larranaga, MD, provides his opinion regarding the criticality of urgency in LN treatment.

Key opinion leaders discuss aspects driving care pathways for patients with lupus nephritis.

Alvin Wells, MD, PhD, and Jorge Larranaga, MD, highlight the goals of treatment for patients with lupus nephritis.

Alvin Wells, MD, PhD, provides an overview of the lupus nephritis treatment landscape.

Expert panelists share strategies and considerations for selecting optimal treatment pathways for patients with lupus nephritis.

Belimumab and voclosporin are highlighted as key contributors to the lupus nephritis treatment landscape.

Jorge Larranaga, MD, discusses the AURORA 2 study and its emphasis on voclosporin.

Drs Larranaga and Wells describe challenges impacting access to care for patients with LN.

Drs Wells and Larranaga discuss unmet needs in the treatment landscape for patients with lupus nephritis.

In their closing thoughts, experts emphasize their optimism regarding the direction of LN treatment strategies and resources.